Phase 2CompletedAge-related condition
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (Wet AMD)
- Sponsor
- Unity Biotechnology, Inc. (Industry)
- Enrollment
- 51 enrolled
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- UBX1325 injection 50 μL; EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Ages
- adults, older adults
- Registry
- NCT05275205
Full record on ClinicalTrials.gov
From the registry
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Primary outcomes
- Treatment Emergent Adverse Events (TEAEs) Will be Evaluated for Ocular and Systemic Safety and Tolerability of a Repeat IVT Injection of UBX1325 Compared to Active Control
History
Results first posted
Last registry update
Study completion
Primary completion
Registered
Started